In this video, the MIRASOL trial (GOG 3045/ENGOT OV-55) was discussed, focusing on the evaluation of the safety and efficacy of mirvetuximab soravtansine-gynx in comparison to chemotherapy.
We have the privilege of hearing from two distinguished Belgian experts the results of the study presented as a late breaking abstract at ASCO 2023. Prof. Van Gorp, a renowned gynaecological oncologist and co-author of the abstract, and Prof. Hannelore Denys, a distinguished medical oncologist from UZ Gent, provide their expertise to explain and discuss the study and its consequences.
Stay informed as MediMix continues to bring you the latest updates on the MIRASOL trial and other ground-breaking research in gynaecological oncology. We are committed to keeping you up-to-date with the most relevant scientific advancements that can make a difference in clinical practice.
With the educational support of:
